Literature DB >> 32784004

Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.

Ansab Akhtar1, Mahendra Bishnoi2, Sangeeta Pilkhwal Sah3.   

Abstract

Sporadic Alzheimer's disease (sAD) is the most common type of dementia and progressive neurodegenerative disease. To establish the sAD model, intracerebroventricular (ICV) streptozotocin (STZ) at a dose of 3 mg/kg was administered bilaterally in rats on a stereotaxic apparatus. Behavioral tests such as Morris water maze (MWM), novel object recognition (NOR) and open field test were performed to evaluate cognitive and locomotor functions. Two treatment doses (5 mg/kg and 10 mg/kg) of sodium orthovanadate (SOV) and rivastigmine (2 mg/kg) were given orally to ICV-STZ induced rats for 21 days. Cortical and hippocampal tissues were dissected. Estimation of oxidative stress, mitochondrial dysfunction as complex I, II, III, IV activity, cholinergic function as acetylcholinesterase activity, ELISA for phosphorylated tau protein and insulin degrading enzyme (IDE), neuroinflammation as NF-κB gene expression and insulin signaling functioning as Q-RT-PCR for IR, IRS-1, PI3K, AKT, GSK-3β gene expression were performed. Behavioral results with SOV and rivastigmine treatment revealed decreased escape latency and increased discrimination index in MWM and NOR respectively. Treatment results with SOV also demonstrated attenuation of oxidative imbalance, improved mitochondrial activity, and reversed IDE and tau pathology. SOV treatment upregulated gene expression of IR, IRS-1, PI3K, and AKT, and downregulated that of GSK-3β. SOV results were compared with standard drug rivastigmine. Conclusively, the memory enhancement by SOV was mediated through oxidative balance, mitochondrial enzyme complex activation, and improved insulin signaling regulation. However, the primary mechanism of SOV remained attenuation of tau pathology by the upregulation of IRS-1/PI3K/AKT/GSK-3β pathway and reversal of insulin resistance in terms of IDE. Hence, in sAD paradigm, SOV contributed to memory improvement evident with the findings of behavioral studies, which can further potentially have clinical significance in AD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; ICV-STZ; Insulin resistance; Mitochondrial dysfunction; Oxidative stress; Sodium orthovanadate

Year:  2020        PMID: 32784004     DOI: 10.1016/j.brainresbull.2020.08.001

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  10 in total

1.  7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer's disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance.

Authors:  Ansab Akhtar; Jatinder Dhaliwal; Sangeeta Pilkhwal Sah
Journal:  Psychopharmacology (Berl)       Date:  2021-03-27       Impact factor: 4.530

2.  Rivastigmine Reverses the Decrease in Synapsin and Memory Caused by Homocysteine: Is There Relation to Inflammation?

Authors:  Osmar Vieira Ramires Junior; Tiago Marcon Dos Santos; Josiane Silva Silveira; Raíssa Leite-Aguiar; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2022-05-17       Impact factor: 5.590

3.  Roflumilast Reduces Pathological Symptoms of Sporadic Alzheimer's Disease in Rats Produced by Intracerebroventricular Streptozotocin by Inhibiting NF-κB/BACE-1 Mediated Aβ Production in the Hippocampus and Activating the cAMP/BDNF Signalling Pathway.

Authors:  Noorul Hasan; Saima Zameer; Abul Kalam Najmi; Suhel Parvez; Mohd Akhtar
Journal:  Neurotox Res       Date:  2022-02-22       Impact factor: 3.911

4.  Cinnamaldehyde Regulates Insulin and Caspase-3 Signaling Pathways in the Sporadic Alzheimer's Disease Model: Involvement of Hippocampal Function via IRS-1, Akt, and GSK-3β Phosphorylation.

Authors:  Saeid Bagheri-Mohammadi; Sahar Askari; Behrang Alani; Maryam Moosavi; Rasoul Ghasemi
Journal:  J Mol Neurosci       Date:  2022-10-10       Impact factor: 2.866

5.  A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: An Exploratory Study.

Authors:  Yu-Kai Lin; Chih-Sung Liang; Chia-Kuang Tsai; Chia-Lin Tsai; Jiunn-Tay Lee; Yueh-Feng Sung; Chung-Hsing Chou; Hung-Sheng Shang; Bing-Heng Yang; Guan-Yu Lin; Ming-Wei Su; Fu-Chi Yang
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

6.  Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.

Authors:  Noorul Hasan; Saima Zameer; Abul Kalam Najmi; Suhel Parvez; Mohammad Shahar Yar; Mohd Akhtar
Journal:  Pharmacol Rep       Date:  2021-04-15       Impact factor: 3.024

Review 7.  Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease.

Authors:  Mingcui Zheng; Pengwen Wang
Journal:  3 Biotech       Date:  2021-03-20       Impact factor: 2.406

Review 8.  Targeting Impaired Nutrient Sensing via the Glycogen Synthase Kinase-3 Pathway With Therapeutic Compounds to Prevent or Treat Dementia: A Systematic Review.

Authors:  Adrian Matysek; Sumudu Perera Kimmantudawage; Lei Feng; Andrea B Maier
Journal:  Front Aging       Date:  2022-07-18

9.  Comparative Phosphoproteomics of Neuro-2a Cells under Insulin Resistance Reveals New Molecular Signatures of Alzheimer's Disease.

Authors:  Dayea Kim; Yeon Suk Jo; Han-Seul Jo; Sungwon Bae; Yang Woo Kwon; Yong-Seok Oh; Jong Hyuk Yoon
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

Review 10.  Role of Cholinergic Signaling in Alzheimer's Disease.

Authors:  Zhi-Ru Chen; Jia-Bao Huang; Shu-Long Yang; Fen-Fang Hong
Journal:  Molecules       Date:  2022-03-10       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.